Engflag

Bexepril

Quick links to important sections

Bexepril

Bexepril_EN

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive

Treatment option: Hyperlipidemia, Hypertension, Diabetic Kidney Disease, Cerebrovascular Accident, Smoking, Smoking Cessation, Diabetes Mellitus, Heart Failure, Heart Attack

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bexepril

Quick Facts

Property Description
Active ingredient Benazepril hydrochloride
Form Oral tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common purpose Antihypertensive agent
Origin Synthetic compound

What Type of Medicine is Bexepril?

Bexepril is a prescription-only medicine containing the active ingredient Benazepril hydrochloride. This substance is a synthetic chemical compound that belongs to the Angiotensin-Converting Enzyme (ACE) inhibitor pharmacological class. Bexepril is a single-ingredient product designed to be taken as an oral tablet.

An important characteristic of Benazepril is its classification as a prodrug; this means the compound is biologically inactive when ingested and must be metabolized by the liver into its potent active therapeutic form, Benazeprilat. This mechanism is clinically recognized as supporting sustained pharmacological activity, a key feature differentiating it from first-generation ACE inhibitors.

Bexepril's General Function and Cardiovascular Role

Bexepril's general purpose is to act as an antihypertensive agent, helping to maintain blood pressure within a healthier range, which is essential for patients needing consistent blood pressure control. Benazepril achieves its effect through the fundamental mechanism of inhibiting the Angiotensin-Converting Enzyme.

By intervening in this regulatory pathway, Bexepril prevents the formation of a potent natural substance that narrows blood vessels. This results in vasodilation (widening of blood vessels), which reduces the resistance to blood flow and lowers systemic arterial blood pressure. Consequently, the medicine provides cardiovascular support by alleviating mechanical strain on the heart and arteries.

What side effects are possible with Bexepril?

Possible Side Effects and Safety Information

The official safety profile for Benazepril (Bexepril) is defined by government regulatory documents, which formally classify potential adverse reactions by the frequency and organ system affected. The most frequently reported adverse reactions are classified as Common, occurring in ge 1/100 to < 1/10 treated patients. These typically involve Headache, Cough (a known effect of the ACE inhibitor class), and Dizziness.

System-Organ-Class Safety Summary

Adverse effects are documented across several physiological systems. The label notes Nervous System Disorders (headache, dizziness), Respiratory, Thoracic and Mediastinal Disorders (cough), and Vascular Disorders (hypotension, or low blood pressure). Gastrointestinal Disorders such as nausea and diarrhea are also listed, alongside reactions affecting the Skin and Subcutaneous Tissue.

Serious Adverse Reactions and Restrictions

Regulatory documents emphasize the risk of Serious Adverse Reactions, which are rare but critical. These include Angioedema (swelling of the face, lips, tongue, or larynx) and the potential progression of Cholestatic Jaundice to Hepatic Failure. Specific safety restrictions apply: the medicine is contraindicated during the second and third trimesters of pregnancy due to risk of harm to the fetus. Furthermore, patients with a history of Angioedema related to previous ACE inhibitor use, or those with Bilateral Renal Artery Stenosis, face particular risk considerations.

Time and Population Notes

The label notes that Symptomatic Hypotension and dizziness are often more likely to occur upon the initial dose or following a dose increase. Specific safety caution is advised for patient groups, including Black patients (who may have a higher risk of angioedema) and patients with impaired renal function (due to the risk of hyperkalemia and worsening function).

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The information provided in this section reflects only the officially documented descriptions of overdose and mandated emergency actions as stated in government regulatory sources for Benazepril (Bexepril).

Documented Manifestations and Severe Outcomes

Overdose is primarily characterized by an exaggerated pharmacological effect, most notably severe hypotension (extremely low blood pressure). Additional regulator-listed clinical manifestations include bradycardia (slow heart rate) and related orthostatic effects.

Severe or life-threatening outcomes documented in official labeling include Circulatory Shock and Acute Renal Failure resulting from profound, uncorrected hypotension.

Emergency Actions and Management

Immediate medical attention must be sought for any suspected overdose. Official guidance mandates that individuals or caregivers contact emergency services immediately if symptoms such as fainting, dizziness, or signs of extremely low blood pressure are observed.

Management is strictly defined as symptomatic and supportive treatment. Regulatory documents confirm that no specific antidote is known for Benazepril overdose. Due to the risk of severe instability, hospital monitoring is required to continuously observe vital signs and manage complications. Supportive interventions, such as intravenous fluid replacement and, in certain cases, procedures like hemodialysis, are described in official management protocols.

Therapeutic Uses of Bexepril

Quick Facts: Uses of Bexepril

  • Hypertension (High Blood Pressure): Helps manage and control blood pressure levels.
  • Heart Failure: Used as adjunctive therapy to manage the symptoms of heart failure.
  • Acute Myocardial Infarction (Heart Attack): May be used to support patient outcomes following a heart attack.

Bexepril is a medication indicated for the management of several cardiovascular conditions. It is frequently prescribed to help control high blood pressure, also known as hypertension, which helps support the overall health of blood vessels.

The medication is also used as an important component of the treatment plan for heart failure. In this context, it may help in the management of related signs and symptoms.

Furthermore, Bexepril is used to help improve survival and reduce the risk of further complications when administered to patients following an acute myocardial infarction (heart attack). These applications represent the established therapeutic uses for the medication.

It is important to understand that Bexepril is part of a long-term management strategy and does not represent a cure for these chronic conditions. Treatment must always follow the guidance and supervision of a qualified healthcare professional.

Eligibility and Restrictions for Use

Eligibility Scope

Scope Element Official Regulatory Statement
Populations for whom use is allowed Adults with approved indications. Pediatric patients 6 years and older for the treatment of hypertension.
Populations for whom use is not recommended Pregnant patients in the first trimester. Breastfeeding patients (due to excretion in human milk).
Populations for whom use is contraindicated Patients with a history of Angioedema related to any prior ACE inhibitor. Patients with Hereditary or Idiopathic Angioedema. Diabetic patients also taking Aliskiren. Patients taking Neprilysin Inhibitors (must be 36 hours apart). Pregnant patients in the second and third trimesters.

Eligibility and Restriction Rules

Classification Rule
Age-Related Restrictions Contraindicated in children under 6 years (safety/efficacy not established). Also contraindicated for pediatric patients with a GFR less than 30 mL/ min/ 1.73 m^2.
Condition-Specific Rules Use requires caution and monitoring in patients with Impaired Renal Function (GFR le 30 mL/ min) and Hepatic Impairment. Caution is also specified for patients with Aortic Stenosis or Obstructive Hypertrophic Cardiomyopathy.
Physiological Status The medicine is contraindicated during the 2nd and 3rd trimesters of pregnancy; discontinuation is mandatory upon detection of pregnancy. Use is not recommended while breastfeeding.

The official regulatory documents establish eligibility by imposing absolute contraindications for patients with a history of Angioedema or those with specific drug-disease interactions, such as Aliskiren use in diabetics. Eligibility is also subject to conditional use based on organ function, with use restricted or requiring careful monitoring in cases of renal impairment. These rules clearly define who is permitted, restricted, or prohibited from using Bexepril.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bexepril’s interaction profile is structured around combinations that are officially prohibited and those that cause significant changes in physiological response or drug exposure, as documented by regulatory agencies.

Contraindicated Combinations

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) is strictly contraindicated due to a highly increased risk of Angioedema. A mandatory 36-hour separation period must be observed when switching to or from these agents. Use with Aliskiren is contraindicated in patients with diabetes mellitus.

Pharmacodynamic and Exposure Effects

Interactions may lead to additive effects on electrolyte balance and blood pressure. The co-administration of Potassium Supplements or Potassium-Sparing Diuretics (e.g., Spironolactone) presents a risk of Hyperkalemia (elevated serum potassium) due to additive potassium-retaining effects.

Other agents that lower blood pressure, including other antihypertensive drugs, may cause additive hypotensive effects. Similarly, combining Bexepril with mTOR Inhibitors (e.g., Sirolimus) is documented to increase the risk of Angioedema.

Co-administration with Lithium results in increased serum concentrations of Lithium, raising the risk of toxicity, a finding attributed to reduced renal clearance of Lithium. NSAIDs may reduce the antihypertensive effectiveness of Bexepril and are associated with a potential for renal function deterioration. General food intake does not clinically alter the bioavailability of the active compound.

Mechanism of Action

Targeting the Angiotensin-Converting Enzyme (ACE)

Bexepril's mechanism begins when its active metabolite, Benazeprilat, competitively inhibits the Angiotensin-Converting Enzyme (ACE). By blocking this enzyme, the drug suppresses the primary biochemical step responsible for creating the powerful vasoconstrictor, Angiotensin II, thereby modulating a key humoral system that regulates vascular tone. This molecular action modulates constrictive signaling within the circulatory system.

Dual Effect on Vasoactive Peptides and Fluid Balance

The inhibition of ACE results in a dual physiological consequence. The block reduces vasoconstriction from Angiotensin II and prevents the degradation of the natural vasodilator, Bradykinin, promoting vessel relaxation. Furthermore, the resulting decrease in Angiotensin II reduces Aldosterone secretion, which promotes natriuresis and diuresis via the kidneys. This combined mechanistic effect results in both the widening of blood vessels and a reduction in circulating fluid volume, altering the hemodynamic parameters of the circulatory system.

Prodrug Activation and Onset of Action

Bexepril is classified as a prodrug, meaning the administered compound (Benazepril) is inactive and must first be metabolized by the liver into its potent inhibitor form, Benazeprilat. This metabolic activation is the rate-limiting step for the onset of the inhibitory action on ACE.

Dosage and Administration Information

Official Administration and Dosage Guidelines

Bexepril (Benazepril hydrochloride) is strictly an oral medication. It is supplied as tablets in four specific strengths: 5 mg, 10 mg, 20 mg, and 40 mg. The medication is used as part of a long-term treatment plan, with the total daily dose generally administered once per day.

Usage Instruction Standard Adult Regimen Population-Specific Rules
Route & Frequency Oral, once daily (or divided into two equal doses). Use is not recommended for children under 6 years of age.
Starting Dose 10 mg once daily (for patients not taking a diuretic). Initial dose is 5 mg once daily for patients already receiving a diuretic.
Maintenance Dose Typically 20 mg to 40 mg per day. Maximum daily dose is 80 mg. For adults with kidney impairment (GFR < 30 mL/min), the initial dose is 5 mg once daily, not to exceed 40 mg total per day.
Food Intake May be taken with or without food, as absorption is not significantly affected by meals. Pediatric dosing (≥ 6 years) starts at 0.2 mg/kg once daily, with a maximum of 40 mg daily.

For patients unable to swallow tablets, an oral suspension can be prepared using standard compounding instructions. This liquid form requires refrigeration and must be discarded after 30 days. A general procedural step for a missed dose is to take it as soon as possible, unless it is nearly time for the next scheduled dose.

Recent Clinical Evidence

Evidence for use in High Blood Pressure (Hypertension)

Research has conducted studies evaluating Bexepril in individuals with hypertension, including Randomized Controlled Trials (RCTs) that examined outcomes related to physiological strain. These studies focused primarily on measured changes in systolic and diastolic blood pressure (BP), including 24-hour monitoring. Research also studied major cardiovascular outcomes and structural markers like left ventricular mass. It remains notable that dedicated long-term research focusing solely on Benazepril as a single agent is limited, with much information derived from studies using fixed-dose combinations with other treatments. Data patterns related to outcomes may also vary across different racial and ethnic populations that were studied.

Evidence for use in Heart Failure and Post-Heart Attack Support

Bexepril was studied for its use in individuals with functional limitations related to heart failure and following an acute myocardial infarction (heart attack). Studies examined the class of medicines to which Bexepril belongs, reporting patterns where the incidence of all-cause mortality and cardiovascular events was observed to be lower, and rehospitalization rates were reported to be fewer in studied heart failure populations compared to inactive substances. The evidence base for post-heart attack support is often closely integrated with the research base for heart failure management.

Research in Specific Patient Groups

Studies explored Bexepril in specific groups, such as older adults and individuals with coexisting conditions like impaired kidney function or diabetes. Research in older adults monitored responses and reported patterns generally similar to those observed in studies of younger adult populations. For children 6 years of age and older, studies evaluated outcomes reflecting daily functioning; research data for Benazepril in children under 6 years is not available.

Areas of Research Uncertainty and Study Gaps

The overall evidence quality varies across studies, and certainty remains low in certain areas. The follow-up durations in many major trials are typically limited to a few years. Consequently, there is limited information available for the duration of response and maintenance of measured physiological outcomes when Benazepril is studied alone. Data for certain groups, such as pregnant or breastfeeding individuals, remain insufficient.

Key Studies & References

  1. LOTENSIN (benazepril hydrochloride) tablets, USP - Full Prescribing Information

How should Bexepril be stored and disposed of?

How to Store and Dispose of Bexepril?

The storage and disposal of Bexepril (benazepril hydrochloride) must strictly follow the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C to 30 C are permitted, but the product must not be frozen.
  • Protection: The tablets must be protected from light and moisture.
  • Container: The medicine must be dispensed in a tight and light-resistant container equipped with a child-resistant closure.
  • Child Safety: Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired product and waste material must be disposed of according to local regulatory requirements. This instruction prevents the product from entering the wastewater system or general trash improperly.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBelgium

flagIreland

Equivalent of Bexepril found in:

A-Z Index: